Traws Pharma IncNASDAQ:TRAWNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE4.5106
- TODAY'S CHANGE (%)-0.2310 (-4.8718%)
- Bid / Lots4.5100/ 2
- Ask / Lots4.7000/ 3
- Open / Previous Close4.5800 / 4.7416
- Day Range
- 52 Week Range
- Volume3,298
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TRAW |
|---|---|---|
| 09:32 ET | 127 | 4.58 |
| 10:20 ET | 300 | 4.58 |
| 10:22 ET | 111 | 4.5691 |
| 10:24 ET | 100 | 4.58 |
| 10:26 ET | 200 | 4.58 |
| 11:38 ET | 847 | 4.5106 |
Nov 14, 2024
Press Release: Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results, from 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
4:30PM ET on Thursday Nov 14, 2024 by Dow JonesTraws Pharma Provides Business Update and Reports Q3 2024 Financial Results, from 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Traws Pharma Inc | 14.3M | 0.0x | --- |
AIM ImmunoTech Inc | 14.5M | -0.5x | --- |
Sensei Biotherapeutics Inc | 14.0M | -0.5x | --- |
Minerva Neurosciences Inc | 15.0M | -5.2x | --- |
Cingulate Inc | 13.5M | -0.1x | --- |
NKGen Biotech Inc | 13.4M | -0.1x | --- |
Company Information
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). Narazaciclib’s mechanism of action in LGEEC is validated by phase II studies with other approved CDK4/6 inhibitors: palbociclib, ribociclib, and abemaciclib. Narazaciclib is in phase I/IIa study to define the Phase II dose (RP2D).
Contact Information
- Headquarters
- 12 Penns TrailNEWTOWN, PA, United States 18940
- Phone
- 267-759-3680
- Fax
- 267-759-3681
Executives
- Executive Chairman of the Board
- Iain Dukes
- Chief Executive Officer, Director
- Werner Cautreels
- Chief Operating Officer, Director
- Nikolay Savchuk
- Chief Scientific Officer, Virology
- C. David Pauza
- Chief Medical Officer
- Robert Redfield
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $14.3M |
|---|---|
Revenue (TTM) | $226.0K |
Shares Outstanding | 3.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.47 |
EPS | $-141.34 |
Book Value | $12.70 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 63.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -62,636.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
